Efficacy and safety of irreversible electroporation for malignant liver tumors: a systematic review and meta-analysis
| Autor: | Naveen Kalra, Sreedhara B Chaluvashetty, Harish Bhujade, Pankaj Gupta, Sathya Sagar, Muniraju Maralakunte, Praveen Kumar-M |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Carcinoma Hepatocellular Gastroenterology 030218 nuclear medicine & medical imaging Metastasis 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Overall survival Humans Radiology Nuclear Medicine and imaging Prospective Studies Major complication Retrospective Studies medicine.diagnostic_test business.industry Liver Neoplasms Interventional radiology General Medicine Irreversible electroporation medicine.disease Confidence interval Bile Ducts Intrahepatic Electroporation Treatment Outcome Bile Duct Neoplasms 030220 oncology & carcinogenesis Hepatocellular carcinoma Meta-analysis Radiology business |
| Zdroj: | European Radiology. 31:6511-6521 |
| ISSN: | 1432-1084 0938-7994 |
| DOI: | 10.1007/s00330-021-07742-y |
| Popis: | The data regarding overall survival (OS) and progression-free survival (PFS) following irreversible electroporation (IRE) is scarce. We performed a systematic review of the safety and efficacy of IRE for liver malignancies. Searches of MEDLINE, EMBASE, and SCOPUS databases were performed through September 1, 2019. Studies reporting the survival data (OS and PFS) and complications (graded according to the Society of interventional Radiology classification) were included. A generalized linear mixed method with a random-effects model was used for assessing pooled incidence rates and corresponding 95% confidence intervals (CIs). A total of 25 studies (n = 776, 15 prospective, 10 retrospective) were included. Metastasis, hepatocellular carcinoma, and cholangiocarcinoma were present in 354, 285, and 100 patients, respectively. The pooled OS at 6, 12, 24, and 36 months was 93.28% (95% CI: 63.23–99.12, I2= 67%), 81.29% (95% CI: 69.80–89.22, I2 = 73%), 61.47% (95% CI: 52.81–69.46, I2 = 0%), and 40.88% (95% CI: 28.43–54.61, I2 = 64%), respectively. The pooled PFS at 6, 12, and 24 months was 79.72% (95% CI: 67.88–87.97, I2 = 70%), 64.19% (95% CI: 56.68–71.06, I2 = 57%), 49.05% (95% CI: 11.47–87.73, I2 = 96%), respectively. Overall complication rate was 23.7%. Major complications (grade C-F) occurred in 6.9% patients. IRE is associated with favorable OS and PFS. Although the overall complication rate is high, most complications are graded as minor. • The pooled OS and PFS at 6, 12, and 24 months for all the tumor types was 93.28% and 79.72%, 81.29% and 64.19%, and 61.47% and 49.05%, respectively. • HCC was associated with a better OS at 12 and 36 months. • The overall complication rate was 23.7%, with major complications (SIR grade C-F) comprising 6.9%. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink